Sushi Domain-Containing Protein 3: A Potential Target for Breast Cancer

详细信息    查看全文

• 作者：Zhenghong Yu ; Enze Jiang ; Xinxing Wang ; Yaqin Shi…
• 关键词：Sushi domain ; containing protein 3 ; Breast cancer ; Aromatase inhibitors
• 刊名：Cell Biochemistry and Biophysics
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：72
• 期：2
• 页码：321-324
• 全文大小：331 KB
• 参考文献：1.Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69-0.
  2.Bulun, S. E., Chen, D., Lu, M., et al. (2007). Aromatase excess in cancers of breast, endometrium and ovary. The Journal of Steroid Biochemistry and Molecular Biology, 106, 81-6.PubMed Central PubMed View Article
  3.Dumitrescu, R. G., & Cotarla, I. (2005). Understanding breast cancer risk—where do we stand in 2005? Journal of Cellular and Molecular Medicine, 9, 208-21.PubMed View Article
  4.Jones, M. E., Boon, W. C., McInnes, K., Maffei, L., Carani, C., & Simpson, E. R. (2007). Recognizing rare disorders: Aromatase deficiency. Nature Clinical Practice Endocrinology & Metabolism, 3, 414-21.View Article
  5.Simpson, E. R., & Davis, S. R. (2001). Minireview: Aromatase and the regulation of estrogen biosynthesis—some new perspectives. Endocrinology, 142, 4589-594.PubMed
  6.Bulun, S. E., Lin, Z., Imir, G., et al. (2005). Regulation of aromatase expression in estrogen-responsive breast and uterine disease: From bench to treatment. Pharmacological Reviews, 57, 359-83.PubMed View Article
  7.Shibaya, M., Matsuda, A., Hojo, T., Acosta, T. J., & Okuda, K. (2007). Expressions of estrogen receptors in the bovine corpus luteum: Cyclic changes and effects of prostaglandin F2alpha and cytokines. Journal of Reproduction and Development, 53, 1059-068.PubMed View Article
  8.Zuo, Y., Berdeaux, R., & Frost, J. A. (2014). The RhoGEF Net1 is required for normal mammary gland development. Molecular Endocrinology, 28(12), 1948-960.PubMed View Article
  9.Oh, Y., Rosenfeld, R., & Ingermann, A.R. (2009). Comprises nucleotide sequences coding insulin-like growth factor binding protein-3 and receptors for diagnosis, prevention and treatment of cancer; antitumor/anticarcinogenic agents. Google Patents, 2009.
  10.Bulun, S. E., Chen, D., Moy, I., Brooks, D. C., & Zhao, H. (2012). Aromatase, breast cancer and obesity: A complex interaction. Trends in Endocrinology and Metabolism: TEM, 23, 83-9.PubMed Central PubMed View Article
  11.Diaz-Cruz, E. S., Sugimoto, Y., Gallicano, G. I., Brueggemeier, R. W., & Furth, P. A. (2011). Comparison of increased aromatase versus ERalpha in the generation of mammary hyperplasia and cancer. Cancer Research, 71, 5477-487.PubMed Central PubMed View Article
  12.Yamamoto, M., Hosoda, M., Nakano, K., et al. (2014). p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Science, 105, 8.
  13.Sabnis, G., Schayowitz, A., Goloubeva, O., Macedo, L., & Brodie, A. (2009). Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Research, 69, 1416-428.PubMed Central PubMed View Article
  14.Van Asten, K., Neven, P., Lintermans, A., Wildiers, H., & Paridaens, R. (2014). Aromatase inhibitors in the breast cancer clinic: Focus on exemestane. Endocrine-Related Cancer, 21, R31–R49.PubMed View Article
  15.Subik, K., Lee, J. F., Baxter, L., et al. (2010). The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer: Basic and Clinical Research, 4, 35-1.
  16.Lim, S., Janzer, A., Becker, A., et al. (2010). Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis, 31, 512-20.PubMed View Article
  17.Reid, K. B., & Day, A. J. (1989). Structure-function relationships of the complement components. Immunology Today, 10, 177-80.PubMed View Article
  18.Norman, D. G., Barlow, P. N., Baron, M., Day, A. J., Sim, R. B., & Campbell, I. D. (1991). Three-dimensional structure of a complement control protein module in solution. Journal of Molecular Biology, 219, 717-25.PubMed View Article
  19.Gaboriaud, C., Rossi, V., Bally, I., Arlaud, G. J., & Fontecilla-Camps, J. C. (2000). Crystal structure of the catalytic domain of human complement c1s: A serine protease with a handle. EMBO Journal, 19, 1755-765.PubMed Central PubMed View Article
  20.Moy, I., Todorovic, V., Dubash, A. D., et al. (2014). Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells. Oncogene,. doi:10.-038/?onc.-013 .PubMed
  21.Mello-Grand, M., Singh, V., Ghimenti, C., et al. (2010). Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Research and Treatment, 121, 399-11.PubMed View Article
  22.Watson, A. P., Evans, R. L., & Egland, K. A. (2013). Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis. Molecular Cancer Research: MCR, 11, 74-5.PubMed Central PubMed View Article
  23.Cui, H., Kamino, H., Nakamura, Y., et al. (2010). Regulation of
• 作者单位：Zhenghong Yu (1)
  Enze Jiang (2)
  Xinxing Wang (1)
  Yaqin Shi (2)
  Anna Junjie Shangguan (3)
  Luo Zhang (4)
  Jie Li (5)
  
  1. Department of Medical Oncology, Jinling Hospital, Nanjing, Jiangsu, China
  2. School of Medicine, Nanjing University, Nanjing, Jiangsu, China
  3. Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL, USA
  4. Changzhou Traditional Chinese Medicine Hospital, Changzhou, Jiangsu, China
  5. Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China
  
• 刊物主题：Biochemistry, general; Pharmacology/Toxicology; Biotechnology; Cell Biology; Biophysics and Biological Physics;
• 出版者：Springer US
• ISSN：1559-0283

文摘

Aromatase inhibitors (AIs) are the most effective endocrine treatment for estrogen receptor α-positive (ERα+) postmenopausal breast cancer. Identification of biomarkers that are able to predict AIs responsiveness of patients is a key for successful treatment. The currently used biomarkers for tamoxifen responsiveness, which including ERα as well as progesterone receptor can only predict part of the potential responders to AIs treatment. Sushi domain-containing protein 3 (SUSD3) is a potential novel biomarker of AIs responsiveness. The lack of SUSD3 expression in breast cancer tissue can be an important predictor for non-responsiveness to AI. Here we reviewed the property and function of SUSD3, its usage as a biomarker and the practicability for SUSD3 to become a target for immune therapy. We suggest this protein can be potentially measured or targeted for prevention, diagnostic, and therapeutic purposes for estrogen or progesterone-dependent disorders including breast cancer in women.